-
1
-
-
45449114994
-
Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded
-
Cattaneo, R, Miest, T, Shashkova, EV and Barry, MA (2008). Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6: 529-540.
-
(2008)
Nat Rev Microbiol
, vol.6
, pp. 529-540
-
-
Cattaneo, R.1
Miest, T.2
Shashkova, E.V.3
Barry, M.A.4
-
2
-
-
84884594361
-
Optim: A randomized phase iii trial of talimogene laherparepvec (t-vec) versus subcutaneous (sc) granulocyte-macrophage colonystimulating factor (gm-csf) for the treatment (tx) of unresected state iiib/c and iv melanoma
-
(June 20 supplement
-
Hans Ingemar Andtbacka, R, Collichio, FA, Amatruda, T, Senzer, NN, Chesney, J and Delman, KA et al. (2013). OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colonystimulating factor (GM-CSF) for the treatment (tx) of unresected state IIIB/C and IV melanoma. J Clin Oncol 31 (June 20 supplement
-
(2013)
J Clin Oncol
, vol.31
-
-
Hans Ingemar Andtbacka, R.1
Collichio, F.A.2
Amatruda, T.3
Senzer, N.N.4
Chesney, J.5
Delman, K.A.6
-
3
-
-
84857225504
-
Replicating viral vectors for cancer therapy: Strategies to synergize with host immune responses
-
Altomonte, J and Ebert, O (2012). Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses. Microb Biotechnol 5: 251-259.
-
(2012)
Microb Biotechnol
, vol.5
, pp. 251-259
-
-
Altomonte, J.1
Ebert, O.2
-
4
-
-
85027956453
-
Thunder and lightning: Immunotherapy and oncolytic viruses collide
-
Melcher, A, Parato, K, Rooney, CM and Bell, JC (2011). Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 19: 1008-1016.
-
(2011)
Mol Ther
, vol.19
, pp. 1008-1016
-
-
Melcher, A.1
Parato, K.2
Rooney, C.M.3
Bell, J.C.4
-
5
-
-
38649123395
-
Innate immunity tumor microenvironment and oncolytic virus therapy: Friends or foes?
-
Stanford, MM, Breitbach, CJ, Bell, JC and McFadden, G (2008). Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr Opin Mol Ther 10: 32-37.
-
(2008)
Curr Opin Mol Ther
, vol.10
, pp. 32-37
-
-
Stanford, M.M.1
Breitbach, C.J.2
Bell, J.C.3
McFadden, G.4
-
6
-
-
77950933188
-
Interference of cd40l-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus
-
Galivo, F, Diaz, RM, Thanarajasingam, U, Jevremovic, D, Wongthida, P, Thompson, J et al. (2010). Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther 21: 439-450.
-
(2010)
Hum Gene Ther
, vol.21
, pp. 439-450
-
-
Galivo, F.1
Diaz, R.M.2
Thanarajasingam, U.3
Jevremovic, D.4
Wongthida, P.5
Thompson, J.6
-
7
-
-
76749162295
-
Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for vsv therapy of b16 melanoma
-
Galivo, F, Diaz, RM, Wongthida, P, Thompson, J, Kottke, T, Barber, G et al. (2010). Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther 17: 158-170.
-
(2010)
Gene Ther
, vol.17
, pp. 158-170
-
-
Galivo, F.1
Diaz, R.M.2
Wongthida, P.3
Thompson, J.4
Kottke, T.5
Barber, G.6
-
8
-
-
34548062828
-
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow
-
Breitbach, CJ, Paterson, JM, Lemay, CG, Falls, TJ, McGuire, A, Parato, KA et al. (2007). Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 15: 1686-1693.
-
(2007)
Mol Ther
, vol.15
, pp. 1686-1693
-
-
Breitbach, C.J.1
Paterson, J.M.2
Lemay, C.G.3
Falls, T.J.4
McGuire, A.5
Parato, K.A.6
-
9
-
-
77951838524
-
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice
-
Kottke, T, Hall, G, Pulido, J, Diaz, RM, Thompson, J, Chong, H et al. (2010). Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest 120: 1551-1560.
-
(2010)
J Clin Invest
, vol.120
, pp. 1551-1560
-
-
Kottke, T.1
Hall, G.2
Pulido, J.3
Diaz, R.M.4
Thompson, J.5
Chong, H.6
-
10
-
-
77953172635
-
Type iii ifn interleukin-28 mediates the antitumor efficacy of oncolytic virus vsv in immune-competent mouse models of cancer
-
Wongthida, P, Diaz, RM, Galivo, F, Kottke, T, Thompson, J, Pulido, J et al. (2010). Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res 70: 4539-4549.
-
(2010)
Cancer Res
, vol.70
, pp. 4539-4549
-
-
Wongthida, P.1
Diaz, R.M.2
Galivo, F.3
Kottke, T.4
Thompson, J.5
Pulido, J.6
-
11
-
-
34047262198
-
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus
-
Diaz, RM, Galivo, F, Kottke, T, Wongthida, P, Qiao, J, Thompson, J et al. (2007). Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 67: 2840-2848.
-
(2007)
Cancer Res
, vol.67
, pp. 2840-2848
-
-
Diaz, R.M.1
Galivo, F.2
Kottke, T.3
Wongthida, P.4
Qiao, J.5
Thompson, J.6
-
12
-
-
38049051428
-
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive t cell therapy, oncolytic virotherapy and immunotherapy
-
Qiao, J, Kottke, T, Willmon, C, Galivo, F, Wongthida, P, Diaz, RM et al. (2008). Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 14: 37-44.
-
(2008)
Nat Med
, vol.14
, pp. 37-44
-
-
Qiao, J.1
Kottke, T.2
Willmon, C.3
Galivo, F.4
Wongthida, P.5
Diaz, R.M.6
-
13
-
-
40749090005
-
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus
-
Qiao, J, Wang, H, Kottke, T, White, C, Twigger, K, Diaz, RM et al. (2008). Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 14: 259-269.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 259-269
-
-
Qiao, J.1
Wang, H.2
Kottke, T.3
White, C.4
Twigger, K.5
Diaz, R.M.6
-
14
-
-
44849140982
-
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (dearing type 3) during a phase i clinical trial
-
White, CL, Twigger, KR, Vidal, L, De Bono, JS, Coffey, M, Heinemann, L et al. (2008). Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 15: 911-920.
-
(2008)
Gene Ther
, vol.15
, pp. 911-920
-
-
White, C.L.1
Twigger, K.R.2
Vidal, L.3
De Bono, J.S.4
Coffey, M.5
Heinemann, L.6
-
15
-
-
0036842215
-
Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
-
Dvorak, HF (2002). Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4368-4380
-
-
Dvorak, H.F.1
-
16
-
-
47949089077
-
Vegf-targeted therapy: Mechanisms of anti-tumour activity
-
Ellis, LM and Hicklin, DJ (2008). VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591.
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 579-591
-
-
Ellis, L.M.1
Hicklin, D.J.2
-
17
-
-
0842311621
-
Vascular targeting agents as cancer therapeutics
-
Thorpe, PE (2004). Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415-427.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 415-427
-
-
Thorpe, P.E.1
-
18
-
-
33747519945
-
Striking out at disseminated metastases: The systemic delivery of oncolytic viruses
-
Fisher, K (2006). Striking out at disseminated metastases: the systemic delivery of oncolytic viruses. Curr Opin Mol Ther 8: 301-313.
-
(2006)
Curr Opin Mol Ther
, vol.8
, pp. 301-313
-
-
Fisher, K.1
-
19
-
-
33646583209
-
Virus smuggling, tax evasion and tumor assassination
-
Harrington, K and Vile, R (2006). Virus smuggling, tax evasion and tumor assassination. Nat Med 12: 507-509.
-
(2006)
Nat Med
, vol.12
, pp. 507-509
-
-
Harrington, K.1
Vile, R.2
-
20
-
-
33748088164
-
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
-
Fulci, G, Breymann, L, Gianni, D, Kurozomi, K, Rhee, SS, Yu, J et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A 103: 12873-12878.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 12873-12878
-
-
Fulci, G.1
Breymann, L.2
Gianni, D.3
Kurozomi, K.4
Rhee, S.S.5
Yu, J.6
-
21
-
-
45749096230
-
Treg depletion-enhanced il-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus
-
Kottke, T, Galivo, F, Wongthida, P, Diaz, RM, Thompson, J, Jevremovic, D et al. (2008). Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol Ther 16: 1217-1226.
-
(2008)
Mol Ther
, vol.16
, pp. 1217-1226
-
-
Kottke, T.1
Galivo, F.2
Wongthida, P.3
Diaz, R.M.4
Thompson, J.5
Jevremovic, D.6
-
22
-
-
59449108246
-
Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated treg modulation and interleukin-2
-
Kottke, T, Thompson, J, Diaz, RM, Pulido, J, Willmon, C, Coffey, M et al. (2009). Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res 15: 561-569.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 561-569
-
-
Kottke, T.1
Thompson, J.2
Diaz, R.M.3
Pulido, J.4
Willmon, C.5
Coffey, M.6
-
23
-
-
80053566728
-
Precise scheduling of chemotherapy primes vegf-producing tumors for successful systemic oncolytic virotherapy
-
Kottke, T, Chester, J, Ilett, E, Thompson, J, Diaz, R, Coffey, M et al. (2011). Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy. Mol Ther 19: 1802-1812.
-
(2011)
Mol Ther
, vol.19
, pp. 1802-1812
-
-
Kottke, T.1
Chester, J.2
Ilett, E.3
Thompson, J.4
Diaz, R.5
Coffey, M.6
-
24
-
-
58149359320
-
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity
-
Prestwich, RJ, Errington, F, Ilett, EJ, Morgan, RS, Scott, KJ, Kottke, T et al. (2008). Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 14: 7358-7366.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7358-7366
-
-
Prestwich, R.J.1
Errington, F.2
Ilett, E.J.3
Morgan, R.S.4
Scott, K.J.5
Kottke, T.6
-
25
-
-
67650375869
-
Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication
-
Prestwich, RJ, Ilett, EJ, Errington, F, Diaz, RM, Steele, LP, Kottke, T et al. (2009). Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 15: 4374-4381.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4374-4381
-
-
Prestwich, R.J.1
Ilett, E.J.2
Errington, F.3
Diaz, R.M.4
Steele, L.P.5
Kottke, T.6
-
26
-
-
79955520856
-
Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization
-
Ilett, EJ, Bárcena, M, Errington-Mais, F, Griffin, S, Harrington, KJ, Pandha, HS et al. (2011). Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res 17: 2767-2776.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 2767-2776
-
-
Ilett, E.J.1
Bárcena, M.2
Errington-Mais, F.3
Griffin, S.4
Harrington, K.J.5
Pandha, H.S.6
-
27
-
-
78349299472
-
Reo-10: A phase i study of intravenous reovirus and docetaxel in patients with advanced cancer
-
Comins, C, Spicer, J, Protheroe, A, Roulstone, V, Twigger, K, White, CM et al. (2010). REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 16: 5564-5572.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 5564-5572
-
-
Comins, C.1
Spicer, J.2
Protheroe, A.3
Roulstone, V.4
Twigger, K.5
White, C.M.6
-
28
-
-
77953093863
-
Two-stage phase i dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers
-
Harrington, KJ, Karapanagiotou, EM, Roulstone, V, Twigger, KR, White, CL, Vidal, L et al. (2010). Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 16: 3067-3077.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 3067-3077
-
-
Harrington, K.J.1
Karapanagiotou, E.M.2
Roulstone, V.3
Twigger, K.R.4
White, C.L.5
Vidal, L.6
-
29
-
-
77953539465
-
Clinical trials with oncolytic reovirus: Moving beyond phase i into combinations with standard therapeutics
-
Harrington, KJ, Vile, RG, Melcher, A, Chester, J and Pandha, HS (2010). Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 21: 91-98.
-
(2010)
Cytokine Growth Factor Rev
, vol.21
, pp. 91-98
-
-
Harrington, K.J.1
Vile, R.G.2
Melcher, A.3
Chester, J.4
Pandha, H.S.5
-
30
-
-
58149252477
-
A phase i study of intravenous oncolytic reovirus type 3 dearing in patients with advanced cancer
-
Vidal, L, Pandha, HS, Yap, TA, White, CL, Twigger, K, Vile, RG et al. (2008). A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 14: 7127-7137.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7127-7137
-
-
Vidal, L.1
Pandha, H.S.2
Yap, T.A.3
White, C.L.4
Twigger, K.5
Vile, R.G.6
-
31
-
-
58149382037
-
Reovirus therapy in cancer: Has the orphan virus found a home?
-
Yap, TA, Brunetto, A, Pandha, H, Harrington, K and Debono, JS (2008). Reovirus therapy in cancer: has the orphan virus found a home? Expert Opin Investig Drugs 17: 1925-1935.
-
(2008)
Expert Opin Investig Drugs
, vol.17
, pp. 1925-1935
-
-
Yap, T.A.1
Brunetto, A.2
Pandha, H.3
Harrington, K.4
Debono, J.S.5
-
32
-
-
0032515141
-
Reovirus therapy of tumors with activated ras pathway
-
Coffey, MC, Strong, JE, Forsyth, PA and Lee, PW (1998). Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334.
-
(1998)
Science
, vol.282
, pp. 1332-1334
-
-
Coffey, M.C.1
Strong, J.E.2
Forsyth, P.A.3
Lee, P.W.4
-
33
-
-
0037439809
-
Systemic reovirus therapy of metastatic cancer in immune-competent mice
-
Hirasawa, K, Nishikawa, SG, Norman, KL, Coffey, MC, Thompson, BG, Yoon, CS et al. (2003). Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 63: 348-353.
-
(2003)
Cancer Res
, vol.63
, pp. 348-353
-
-
Hirasawa, K.1
Nishikawa, S.G.2
Norman, K.L.3
Coffey, M.C.4
Thompson, B.G.5
Yoon, C.S.6
-
34
-
-
0036376654
-
Cells as vehicles for cancer gene therapy: The missing link between targeted vectors and systemic delivery?
-
Harrington, K, Alvarez-Vallina, L, Crittenden, M, Gough, M, Chong, H, Diaz, RM et al. (2002). Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Hum Gene Ther 13: 1263-1280.
-
(2002)
Hum Gene Ther
, vol.13
, pp. 1263-1280
-
-
Harrington, K.1
Alvarez-Vallina, L.2
Crittenden, M.3
Gough, M.4
Chong, H.5
Diaz, R.M.6
-
35
-
-
43049176729
-
Loading of oncolytic vesicular stomatitis virus onto antigen-specific t cells enhances the efficacy of adoptive t-cell therapy of tumors
-
Qiao, J, Wang, H, Kottke, T, Diaz, RM, Willmon, C, Hudacek, A et al. (2008). Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther 15: 604-616.
-
(2008)
Gene Ther
, vol.15
, pp. 604-616
-
-
Qiao, J.1
Wang, H.2
Kottke, T.3
Diaz, R.M.4
Willmon, C.5
Hudacek, A.6
-
36
-
-
33947190925
-
Cell-based delivery of oncolytic viruses: A new strategic alliance for a biological strike against cancer
-
Power, AT and Bell, JC (2007). Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther 15: 660-665.
-
(2007)
Mol Ther
, vol.15
, pp. 660-665
-
-
Power, A.T.1
Bell, J.C.2
-
37
-
-
33645239282
-
Synergistic antitumor effects of immune cell-viral biotherapy
-
Thorne, SH, Negrin, RS and Contag, CH (2006). Synergistic antitumor effects of immune cell-viral biotherapy. Science 311: 1780-1784.
-
(2006)
Science
, vol.311
, pp. 1780-1784
-
-
Thorne, S.H.1
Negrin, R.S.2
Contag, C.H.3
-
38
-
-
84862550301
-
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients
-
Adair, RA, Roulstone, V, Scott, KJ, Morgan, R, Nuovo, GJ, Fuller, M et al. (2012). Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med 4: 138ra77.
-
(2012)
Sci Transl Med
, vol.4
, pp. 138ra77
-
-
Adair, R.A.1
Roulstone, V.2
Scott, K.J.3
Morgan, R.4
Nuovo, G.J.5
Fuller, M.6
-
39
-
-
0036813199
-
Gm-csf-based cancer vaccines
-
Dranoff, G (2002). GM-CSF-based cancer vaccines. Immunol Rev 188: 147-154.
-
(2002)
Immunol Rev
, vol.188
, pp. 147-154
-
-
Dranoff, G.1
-
40
-
-
0027538181
-
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
-
Dranoff, G, Jaffee, E, Lazenby, A, Golumbek, P, Levitsky, H, Brose, K et al. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90: 3539-3543.
-
(1993)
Proc Natl Acad Sci U S A
, vol.90
, pp. 3539-3543
-
-
Dranoff, G.1
Jaffee, E.2
Lazenby, A.3
Golumbek, P.4
Levitsky, H.5
Brose, K.6
-
41
-
-
84874937343
-
Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells
-
Adair, RA, Scott, KJ, Fraser, S, Errington-Mais, F, Pandha, H, Coffey, M et al. (2013). Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. Int J Cancer 132: 2327-2338.
-
(2013)
Int J Cancer
, vol.132
, pp. 2327-2338
-
-
Adair, R.A.1
Scott, K.J.2
Fraser, S.3
Errington-Mais, F.4
Pandha, H.5
Coffey, M.6
-
42
-
-
3042634938
-
Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts
-
Babalola, CP, Nightingale, CH and Nicolau, DP (2004). Adjunctive efficacy of granulocyte colony-stimulating factor on treatment of Pseudomonas aeruginosa pneumonia in neutropenic and non-neutropenic hosts. J Antimicrob Chemother 53: 1098-1100.
-
(2004)
J Antimicrob Chemother
, vol.53
, pp. 1098-1100
-
-
Babalola, C.P.1
Nightingale, C.H.2
Nicolau, D.P.3
-
43
-
-
4544382407
-
G-csf induced progenitor mobilization in mice with piga-blood cells
-
Han, B, Unsinger, J, Liu, F, Link, DC and Bessler, M (2004). G-CSF induced progenitor mobilization in mice with PIGA-blood cells. Hematol J 5: 347-352.
-
(2004)
Hematol J
, vol.5
, pp. 347-352
-
-
Han, B.1
Unsinger, J.2
Liu, F.3
Link, D.C.4
Bessler, M.5
-
44
-
-
84875225339
-
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia jx-594 in liver cancer
-
Heo, J, Reid, T, Ruo, L, Breitbach, CJ, Rose, S, Bloomston, M et al. (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19: 329-336.
-
(2013)
Nat Med
, vol.19
, pp. 329-336
-
-
Heo, J.1
Reid, T.2
Ruo, L.3
Breitbach, C.J.4
Rose, S.5
Bloomston, M.6
-
45
-
-
77957253429
-
Optim trial: A phase iii trial of an oncolytic herpes virus encoding gm-csf for unresectable stage iii or iv melanoma
-
Kaufman, HL and Bines, SD (2010). OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 6: 941-949.
-
(2010)
Future Oncol
, vol.6
, pp. 941-949
-
-
Kaufman, H.L.1
Bines, S.D.2
-
46
-
-
84880889917
-
Leukemia cell-rhabdovirus vaccine: Personalized immunotherapy for acute lymphoblastic leukemia
-
Conrad, DP, Tsang, J, Maclean, M, Diallo, JS, Le Boeuf, F, Lemay, CG et al. (2013). Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia. Clin Cancer Res 19: 3832-3843.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 3832-3843
-
-
Conrad, D.P.1
Tsang, J.2
Maclean, M.3
Diallo, J.S.4
Le Boeuf, F.5
Lemay, C.G.6
-
47
-
-
56749164906
-
Use of biological therapy to enhance both virotherapy and adoptive t-cell therapy for cancer
-
Kottke, T, Diaz, RM, Kaluza, K, Pulido, J, Galivo, F, Wongthida, P et al. (2008). Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol Ther 16: 1910-1918.
-
(2008)
Mol Ther
, vol.16
, pp. 1910-1918
-
-
Kottke, T.1
Diaz, R.M.2
Kaluza, K.3
Pulido, J.4
Galivo, F.5
Wongthida, P.6
-
48
-
-
84881310761
-
Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse
-
Boisgerault, N, Kottke, T, Pulido, J, Thompson, J, Diaz, RM, Rommelfanger-Konkol, D et al. (2013). Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. Mol Ther 21: 1507-1516.
-
(2013)
Mol Ther
, vol.21
, pp. 1507-1516
-
-
Boisgerault, N.1
Kottke, T.2
Pulido, J.3
Thompson, J.4
Diaz, R.M.5
Rommelfanger-Konkol, D.6
-
49
-
-
79960125220
-
Broad antigenic coverage induced by vaccination with virus-based cdna libraries cures established tumors
-
Kottke, T, Errington, F, Pulido, J, Galivo, F, Thompson, J, Wongthida, P et al. (2011). Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med 17: 854-859.
-
(2011)
Nat Med
, vol.17
, pp. 854-859
-
-
Kottke, T.1
Errington, F.2
Pulido, J.3
Galivo, F.4
Thompson, J.5
Wongthida, P.6
-
50
-
-
84961914156
-
Adoptive transfer of cytotoxic t lymphocytes targeting two different antigens limits antigen loss and tumor escape
-
Kaluza, K, Kottke, T, Diaz, RM, Rommelfanger, D, Thompson, J and Vile, RG (2012). Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape. Hum Gene Ther 131: 844-854.
-
(2012)
Hum Gene Ther
, vol.131
, pp. 844-854
-
-
Kaluza, K.1
Kottke, T.2
Diaz, R.M.3
Rommelfanger, D.4
Thompson, J.5
Vile, R.G.6
|